KPRX (Kiora Pharmaceuticals, Inc. Common Stock) Stock Analysis - Financials

Kiora Pharmaceuticals, Inc. Common Stock (KPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, KPRX trades at $2.64 with a market cap of $11.12M and a P/E ratio of -1.01. KPRX moved +0.40% today. Year to date, KPRX is +25.71%; over the trailing twelve months it is -15.33%. Its 52-week range spans $1.76 to $4.18. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces KPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are KPRX's key financials?

KPRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. KPRX recently traded at $2.64. Market cap is $11.12M. P/E ratio is -1.01. Revenue is $0.

KPRX Key Metrics

Key financial metrics for KPRX
MetricValue
Price$2.64
Market Cap$11.12M
P/E Ratio-1.01
EPS$-2.60
Dividend Yield0.00%
52-Week High$4.18
52-Week Low$1.76
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$-10.84M
Gross Margin0.00%

KPRX Annual Financials

YearRevenueNet IncomeEPS
2025$0$-10.84M$-2.60
2024$16.02M$3.59M$0.93
2023$0$-12.51M$-2.69
2022$0$-13.58M$-18.55

Latest KPRX News

Recent KPRX Insider Trades

  • Stengone Carmine N. bought 1.25K (~$4.60K) on Sep 11, 2024.
  • Shapiro Aron bought 3.00K (~$10.80K) on Sep 10, 2024.
  • Walters-Hoffert Lisa bought 1.25K (~$4.83K) on Aug 19, 2024.

KPRX Analyst Consensus

1 analysts cover KPRX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about KPRX

What are KPRX's key financials?
KPRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. KPRX recently traded at $2.64. Market cap is $11.12M. P/E ratio is -1.01. Revenue is $0.
Is KPRX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for KPRX. It does not provide personalized investment advice.
KPRX

KPRX